Treatment of Melanoma with Symptomatic Brain Metastases Requiring Steroids

Melanoma brain metastases (MBMs) that cause neurological symptoms and require corticosteroid support represent a distinct clinical challenge. Treatment selection in this setting depends on the degree of steroid dependence, local therapy feasibility, and tumour biology.

Clinical Scenario

This protocol applies to patients with symptomatic MBMs who require steroid therapy. Two patient groups are addressed: those on lower-dose steroids (<10 mg/day prednisolone equivalent) and those with more severe neurological symptoms requiring higher-dose steroids (>10 mg/day prednisolone equivalent) for whom local therapy is not an option. BRAF mutation status and the feasibility of surgical resection are central to the treatment decision in both groups.

Treatment Approach

Management is stratified by steroid dose threshold and BRAF V600 mutation status. Depending on these factors, the approach may involve a combination of targeted agents or an immunotherapy doublet. Neurosurgical resection is considered when an accessible, symptomatic lesion is resectable. For leptomeningeal involvement, additional locoregional options are part of the algorithm. Full regimen details, sequencing, evidence grades, and indication-specific criteria are available in the complete structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

For patients with symptomatic MBMs requiring steroids (<10 mg/day prednisolone or equivalent):
Patients with MBMs and neurological symptoms requiring steroids (>10 mg prednisolone/day or equivalent) for whom local therapy is not an option can be considered for the following:
BRAFi–MEKi if BRAF V600-mutated can be offered [III, A; ESCAT I-A].
Nivolumab–ipilimumab (BRAF-mutated or BRAF-WT) can be offered [III, A].
Neurosurgery should be discussed, especially if an accessible, resectable tumour is causing symptoms as this may render the patient asymptomatic and provide a bridging strategy to nivolumab–ipilimumab [IV, C].
BRAFi–MEKi (if BRAF V600-mutated) [III, A; ESCAT I-A].
Ipilimumab–nivolumab [III, B].
ChT (if BRAF-WT) [IV, C].
Local treatment (RT [III, B] or intrathecal nivolumab [III, C]) can also be considered.

View source ↗